{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:02:23Z","timestamp":1769824943440,"version":"3.49.0"},"reference-count":36,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2503661","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T04:06:12Z","timestamp":1747022772000},"page":"709-718","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective"],"prefix":"10.1080","volume":"28","author":[{"given":"Ankit","family":"Gulati","sequence":"first","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Mittal","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunanda","family":"Kane","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Mayo Clinic College of Medicine and Science","place":["Rochester, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Creveling","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Bires","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah A.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Chanan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit Kumar","family":"Koushik","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navneet","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.03.002"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otac023"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.022"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-320022"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy171"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17570"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.008"},{"key":"e_1_3_4_12_1","unstructured":"Food and Drug Administration. STELARA\u00ae (ustekinumab) product summary; 2020 [cited 2024 Jan 9]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125261s150lbl.pdf"},{"key":"e_1_3_4_13_1","unstructured":"Food and Drug Administration. OMVOH (mirikizumab-mrkz) injection prescribing information; 2023 [cited 2024 May 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761279s000lbl.pdf"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/31.1.72"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.024"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R417"},{"issue":"1","key":"e_1_3_4_18_1","first-page":"A113","article-title":"P105 mirikizumab versus ustekinumab in moderately to severely active ulcerative colitis: maintenance number needed to treat from a network meta-analysis","volume":"73","author":"Dignass A","year":"2024","unstructured":"Dignass A, Redondo I, Richards M, et\u00a0al. P105 mirikizumab versus ustekinumab in moderately to severely active ulcerative colitis: maintenance number needed to treat from a network meta-analysis. Gut. 2024;73(1):A113.","journal-title":"Gut"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"issue":"4","key":"e_1_3_4_21_1","first-page":"7","article-title":"Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study","volume":"18","year":"2022","unstructured":"Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study. Gastroenterol Hepatol. 2022;18(4):7\u20138.","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.025"},{"key":"e_1_3_4_23_1","unstructured":"Micromedex RED BOOK\u00ae; 2024 [Internet]. [cited 2024 May 28]. Available from: https:\/\/www.merative.com\/micromedex-training-center\/red-book"},{"key":"e_1_3_4_24_1","unstructured":"Corporation PMI. Practice management information corporation; 2023 [cited 2024 May 28]. Available from: https:\/\/www.pmiconline.com\/"},{"key":"e_1_3_4_25_1","first-page":"96","article-title":"K5 Real-world dose escalation and associated costs of ustekinumab in the management of ulcerative colitis in the United States: a retrospective database study","volume":"29","author":"Miguel Regueiro TG","year":"2023","unstructured":"Miguel Regueiro TG, Bandyopadhyay A, Fisher D, et\u00a0al. K5 Real-world dose escalation and associated costs of ustekinumab in the management of ulcerative colitis in the United States: a retrospective database study. J Manag Care Spec Pharm. 2023;29:96\u201397.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_4_26_1","unstructured":"Administration FaD. SELARSDI\u2122 (ustekinumab-aekn) injection for subcutaneous use; 2024 [cited 2024 May 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761343s000lbl.pdf"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02590-6"},{"key":"e_1_3_4_29_1","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond MF","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et\u00a0al. Methods for the economic evaluation of health care programmes. Oxford (UK): Oxford University Press; 2015."},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00869-3"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae004"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad045"},{"issue":"8","key":"e_1_3_4_33_1","first-page":"469","article-title":"The economics of biosimilars","volume":"6","author":"Blackstone EA","year":"2013","unstructured":"Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469\u2013478.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.7249\/PE264"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113069"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae020.104"},{"key":"e_1_3_4_37_1","unstructured":"Pharmaceuticals T. Alvotech and Teva Announce U.S. FDA. Approval of SELARSDI\u2122 (ustekinumab-aekn) biosimilar to Stelara\u00ae (ustekinumab); 2024 [cited 2024 May 28]. Available from: https:\/\/www.tevapharm.com\/news-and-media\/latest-news\/alvotech-and-teva-announce-u.s.-fda-approval-of-selarsdi-ustekinumab-aekn-biosimilar-to-stelara-ust\/"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2503661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:46:22Z","timestamp":1766400382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2503661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2503661"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2503661","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}